SCHEMBL5650139

SCHEMBL5650139

CN(C(=O)On1ccnc1-c1cccs1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
USP2 O75604 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 2/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 4/20 0.37
KDM4E B2RXH2 4/20 0.37
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
HSD17B10 Q99714 2/20 0.35
POLB P06746 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
RAB9A P51151 4/20 0.35
NPC1 O15118 3/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 2/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5646441 0.80 LMNA (0.44) ALDH1A1L3MBTL1LMNAKMT2AKDM4E
SCHEMBL5647581 0.80 LMNA (0.43) ALDH1A1L3MBTL1LMNAKMT2AKDM4E
SCHEMBL5645646 0.78 LMNA (0.42) L3MBTL1LMNAKMT2AKDM4ERAB9A
SCHEMBL5648556 0.77 NPSR1 (0.45) ALDH1A1L3MBTL1KMT2AKDM4EHSD17B10
SCHEMBL5648732 0.76 LMNA (0.43) ALDH1A1L3MBTL1LMNAKMT2AKDM4E
SCHEMBL5651868 0.76 L3MBTL1 (0.43) ALDH1A1L3MBTL1LMNAKMT2AKDM4E
SCHEMBL5647041 0.76 L3MBTL1 (0.43) ALDH1A1L3MBTL1LMNAKMT2AKDM4E
SCHEMBL5646701 0.75 KMT2A (0.49) ALDH1A1USP2L3MBTL1KMT2AKDM4E
SCHEMBL5649485 0.75 ALDH1A1 (0.43) ALDH1A1USP2L3MBTL1LMNAKMT2A
SCHEMBL5651410 0.74 LMNA (0.41) ALDH1A1L3MBTL1LMNAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL ALDH1A1 1304/4885USP2 569/4885L3MBTL1 1427/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL ALDH1A1 1599/4885USP2 434/4885L3MBTL1 2654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.